2-bromo-1-[4-fluoro-3-[(methylsulfonyl)amino]phenyl]ethanone | 170688-01-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-bromo-1-[4-fluoro-3-[(methylsulfonyl)amino]phenyl]ethanone
• 英文别名: N-[5-(2-bromoacetyl)-2-fluorophenyl]methanesulfonamide
• CAS: 170688-01-4
• 化学式: C₉H₉BrFNO₃S
• 分子量: 310.144
• InChiKey: VBUOGAWLTFVBDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-bromo-1-[4-fluoro-3-[(methylsulfonyl)amino]phenyl]ethanone 生成 (+/-)-N-[5-[2-iodo-1-(triethylsilyloxy)ethyl]-2-fluorophenyl]methanesufonamide
  参考文献：
  名称：

  US6037362

  摘要：

  公开号：
• 作为产物：
  描述：

  1-[4-fluoro-3-[(methylsulfonyl)amino]phenyl]ethanone 在 溴 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 生成 2-bromo-1-[4-fluoro-3-[(methylsulfonyl)amino]phenyl]ethanone
  参考文献：
  名称：

  Catecholamine surrogates useful as .beta..sub.3 agonists

  摘要：

  公式为##STR1##的化合物或其药学上可接受的盐，其中：A是键，--(CH.sub.2).sub.n --或--CH(B)--，其中n是1到3的整数，B是--CN，--CON(R.sup.9)R.sup.9'或--CO.sub.2 R.sup.7；R.sup.1是较低的烷基，芳基或芳基烷基；R.sup.2是氢，羟基，烷氧基，--CH.sub.2 OH，氰基，--C(O)OR.sup.7，--CO.sub.2 H，--CONH.sub.2，四唑基，--CH.sub.2 NH.sub.2或卤素；##STR2## R.sup.3是氢，烷基，杂环或R.sup.4是氢，烷基或B；R.sup.5，R.sup.5'，R.sup.8，R.sup.8'或R.sup.8"独立地是氢，烷氧基，较低烷基，卤素，--OH，--CN，--(CH.sub.2).sub.n NR.sup.6 COR.sup.7，--CON(R.sup.6)R.sup.6'，--CON(R.sup.6)OR.sup.6'，--CO.sub.2 R.sup.6，--SR.sup.7，--SOR.sup.7，--SO.sub.2 R.sup.7，--N(R.sup.6)SO.sub.2 R.sup.1，--N(R.sup.6)R.sup.6'，--NR.sup.6 COR.sup.7，--OCH.sub.2 CON(R.sup.6)R.sup.6'，--OCH.sub.2 CO.sub.2 R.sup.7或芳基；或R.sup.5和R.sup.5'或R.sup.8和R.sup.8'可以与它们连接的碳原子一起形成芳基或杂环；R.sup.6和R.sup.6'独立地是氢或较低烷基；R.sup.7是较低烷基；R.sup.9是氢，较低烷基，烷基，环烷基，芳基烷基，芳基，杂芳基；或R.sup.9和R.sup.9'可以与它们连接的氮原子一起形成杂环；但是当A是键或--(CH.sub.2).sub.n且R.sup.3是氢或未取代烷基时，R.sup.4是B或取代烷基。这些化合物是β.sub.3肾上腺素受体激动剂，因此在糖尿病、肥胖症和胃肠疾病的治疗中很有用。

  公开号：

  US05776983A1

文献信息

• Novel tricyclic compounds and drug compositions containing same
  申请人：ASAHI KASEI KOGYO KABUSHIKI KAISHA

  公开号：US20030139475A1

  公开（公告）日：2003-07-24

  Compounds having a &bgr;-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc., represented by a general formula (I) and salts thereof, and a process for producing these, and their intermediates, wherein R represents hydrogen or methyl; R 1 represents hydrogen, halogen, hydroxy, benzyloxy, amino, or hydroxymethyl; R 2 represents hydrogen, hydroxymethyl, NHR 3 , SO 2 NR 4 R 4′ , or nitro; R 6 represents hydrogen or lower alkyl; and X represents nitrogen, R 9 represents hydrogen, one of R 7 and R 8 represent hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy.

  具有&bgr;-3肾上腺素受体激动剂的化合物，可用于治疗和预防糖尿病、肥胖症、高脂血症等疾病，其通式表示为(I)，并且包括其盐，以及制备这些化合物和其中间体的方法。其中，R代表氢或甲基；R1代表氢、卤素、羟基、苄氧基、氨基或羟甲基；R2代表氢、羟甲基、NHR3、SO2NR4R4′或硝基；R6代表氢或低碳基；X代表氮；R9代表氢；R7和R8中的一个代表氢，而另一个代表氢、氨基、乙酰氨基或羟基。
• Catecholamine surrogates useful as B3 agonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0659737A2

  公开（公告）日：1995-06-28

  Compounds of the formula or pharmaceutically acceptable salts thereof wherein: A is a bond, -(CH2)n- or -CH(B)-, where n is an integer of 1 to 3 and B is -CN, -CON(R9)R9' or -C02R7; R1 is lower alkyl, aryl or arylalkyl; R2 is hydrogen, hydroxy, alkoxy, -CH20H, cyano, -C(O)OR7 , -C02H, -CONH2, tetrazole, -CH2NH2 or halogen; R3 is hydrogen, alkyl, heterocycle or R4 is hydrogen, alkyl or B; R5, R5', R8, R8' or R8'' are independently hydrogen, alkoxy, lower alkyl, halogen, -OH, -CN, -(CH2)-nNR6COR7, -CON(R6)R6', -CON(R6)OR6', -C02R6, -SR7, -SOR7, -S02R7, -N(R6)SO2R1, -N(R6)R6', -NR6COR7, -OCH2CON(R6)R6', -OCH2CO2R7 or aryl; or R5 and R5' or R8 and R8' may together with the carbon atoms to which they are attached form an aryl or heterocycle; R6 and R6' are independently hydrogen or lower alkyl; and R7 is lower alkyl; R9 is hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or R9 and R9' may together with the nitrogen atom to which they are attached form a hetocycle; with the proviso that when A is a bond or -(CH2)n and R3 is hydrogen or unsubstituted alkyl, then R4 is B or substituted alkyl. These compounds are beta3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.

  式中的化合物 或其药学上可接受的盐类，其中 A 是键、-(CH2)n- 或 -CH(B)-，其中 n 是 1 至 3 的整数，B 是 -CN、-CON(R9)R9' 或 -C02R7； R1 是低级烷基、芳基或芳烷基； R2 是氢、羟基、烷氧基、- 0H、氰基、-C(O)OR7、-C02H、-CONH2、四唑、- NH2 或卤素； R3 是氢、烷基、杂环或卤素。 R4 是氢、烷基或 B； R5、R5'、R8、R8' 或 R8'' 独立地为氢、烷氧基、低级烷基、卤素、-OH、-CN、-( )-nNR6COR7、-CON(R6)R6'、-C02R6、-SR7、-SOR7、-S02R7、-N(R6)SO2R1、-N(R6)R6'、-NR6COR7、-O CON(R6)R6'、-O CO2R7 或芳基；或 R5 和 R5' 或 R8 和 R8'可与它们所连接的碳原子一起形成芳基或杂环； R6 和 R6'独立地为氢或低级烷基；以及 R7 是低级烷基； R9是氢、低级烷基、烷基、环烷基、芳烷基、芳基、杂芳基；或 R9和R9'可与它们所连接的氮原子一起形成一个杂环；但当A是键或-( )n且R3是氢或未取代的烷基时，则R4是B或取代的烷基。这些化合物是β3肾上腺素能受体激动剂，因此可用于治疗糖尿病、肥胖症和胃肠道疾病等。
• NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0882707A1

  公开（公告）日：1998-12-09

  Compounds represented by general formula (I) or salts thereof, a process for producing the same, and intermediates therefor, wherein R represents hydrogen or methyl; R1 represents hydrogen, hologeno, hydroxy, benzyloxy, amino, or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4, or nitro; R6 represents hydrogen or lower alkyl; and X represents nitrogen, oxygen, sulfur, or methylene, provided that when X represents nitrogen, oxygen, or sulfur, then R9 represents hydrogen, one of R7 an R8 represents hydrogen, and the other thereof represents hydrogen, amino, acetylamino, or hydroxy, and when X represents methylene, then R7 and R8 each represents hydrogen and R9 represents hydrogen, amino, etc. They have a β-3 adrenaline receptor agonist and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc.

  通式(I)所代表的化合物或其盐类，以及生产该化合物或其盐类的工艺和中间体，其中R代表氢或甲基；R1代表氢、囟素、羟基、苄氧基、氨基或羟甲基；R2代表氢、羟甲基、NHR3、SO2NR4R4或硝基；R6代表氢或低级烷基；X代表氮、氧、硫或亚甲基，但当X代表氮、氧或硫时，R9代表氢，R7和R8中的一个代表氢，另一个代表氢、氨基、乙酰氨基或羟基；当X代表亚甲基时，R7和R8各自代表氢，R9代表氢、氨基等。它们具有β-3肾上腺素受体激动剂的作用，可作为治疗和预防糖尿病、肥胖症、高脂血症等的药物。
• NOVEL TRICYCLIC COMPOUNDS HAVING SATURATED RINGS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0997458A1

  公开（公告）日：2000-05-03

  Compounds represented by general formula (I) or their salts, having β3 -adrenoceptor agonism and being efficacious when employed in drugs for treating and preventing diabetes, obesity, hyperlipemia, etc. wherein R represents hydrogen or methyl; R1 represents hydrogen, halogeno, hydroxy, benzyloxy, amino or hydroxymethyl; R2 represents hydrogen, hydroxymethyl, NHR3, SO2NR4R4', or nitro (wherein R3 represents hydrogen, methyl, SO2R5, formyl or CONHR6'; R5 represents lower alkyl, benzyl or NR4R4'; R4 and R4' may be the same or different and each represents hydrogen, lower alkyl or benzyl; and R6' represents hydrogen or lower alkyl); R6 represents hydrogen or lower alkyl; n is 1 or 2; X represents secondary nitrogen, oxygen or sulfur; and when n is 1, then one of R7 and R8 represents hydrogen while another represents hydrogen, amino, acetylamino or hydroxy, or when n is 2, then R8 represents hydrogen while R7 represents hydrogen, amino, acetylamino or hydroxy.

  通式(I)所代表的化合物或其盐类，具有 β3-肾上腺素受体激动作用，在用于治疗和预防糖尿病、肥胖症、高血脂症等药物时具有疗效。其中 R 代表氢或甲基；R1 代表氢、卤素、羟基、苄氧基、氨基或羟甲基；R2 代表氢、羟甲基、NHR3、SO2NR4R4'或硝基（其中 R3 代表氢、甲基、SO2R5、甲酰基或 CONHR6'；R5 代表低级烷基、苄基或 NR4R4'；R4 和 R4'可以相同或不同，各自代表氢、低级烷基或苄基；和 R6' 代表氢或低级烷基）；R6 代表氢或低级烷基；n 为 1 或 2；X 代表仲氮、氧或硫；当 n 为 1 时，则 R7 和 R8 中的一个代表氢，而另一个代表氢、氨基、乙酰氨基或羟基，或当 n 为 2 时，则 R8 代表氢，而 R7 代表氢、氨基、乙酰氨基或羟基。
• Catecholamine surrogates useful as beta 3 agonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0659737B1

  公开（公告）日：2003-03-26